Post-traumatic headache phenotypes and clinical characteristics
- PMID: 41370085
- DOI: 10.1177/03331024251404912
Post-traumatic headache phenotypes and clinical characteristics
Abstract
Background/AimPost-traumatic headache often resembles migraine or tension-type headache, but distinct phenotype and clinical characteristics necessitate further delineation. We aimed to characterize the clinical phenotype, headache patterns, associated features and comorbidities, medication patterns and functional impact of post-traumatic headache in an adult population following mild traumatic brain injury.MethodsThis is a cross-sectional analysis of a cohort of adults with post-traumatic headache after mild traumatic brain injury, by any mechanism, evaluated by a neurologist at an outpatient specialized concussion and headache center in Ontario, Canada between February 2021 and October 2023. Data were collected through standardized pre- and during-visit questionnaires. Descriptive statistics are presented.ResultsAmong 405 patients assessed by a neurologist for post-traumatic headache, median time since injury was 37 days (IQR: 13-126). Most patients reported headache 26 + days per month (292, 72.1%). Headache was continuous in 114 (28.1%), whereas in 215 (53.1%) it lasted hours to days. Headache location was unilateral in 174 (43.0%) and bilateral in 159 (39.3%). Headache quality was described as pulsating/throbbing in 260 (64.2%). The median severity was 7/10 (IQR 5-8). Aggravation by routine physical activity was reported in 287 (70.9%), nausea/vomiting in 279 (69.0%), photophobia in 358 (88.4%) and phonophobia in 337 (83.2%). There was no positional preference for 147 patients (36.3%), while 216 (53.3%) preferred lying down/reclined. Acute medication use frequency was reported as 3 + days per week in 218 (53.8%) and daily in 143 (35.3%). Within this cohort, 201 (49.6%) endorsed one or more psychiatric comorbidities. Only 66 (16.3%) had returned to full work/school attendance, while 169 (41.7%) were completely off usual occupational activities post-injury. One hundred seventy-eight (44.0%) reported pending litigation or insurance claims related to their injury, and/or having a work-related injury. Among the 183 (45.2%) who had undergone neuroimaging, 160 (87.9%) studies were reportedly normal, while there were 13 (7.1%) incidental findings and eight (4.3%) injury-related.DiscussionWhile select migraine features such as photophobia, phonophobia and worsening with routine physical activity are common in post-traumatic headache, there are also distinct features, including daily or near daily headache of long duration. The latter may suggest early sensitization in post-traumatic headache. There is an associated high risk of medication overuse headache, given frequent administration of acute medications, as well as high rates of psychiatric comorbidities and functional impairment. Future studies should aim to further delineate the longitudinal clinical, pathophysiological, and treatment response differences between post-traumatic headache and primary migraine.
Keywords: cohort; concussion; headache attributed to trauma; migraine; phenotype; post-traumatic headache.
Conflict of interest statement
Declaration of conflicting interestsThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: A.C.L. has received personal fees from Abbvie, Lundbeck, Organon, Pfizer, and Teva for presentations and consultations, and is involved in research funded by Abbvie, the University of Ottawa Brain and Mind Research Institute (uOBMRI), and the Ontario Brain Institute (OBI) – research funding goes directly to the institution. She is a minority shareholder and is on the leadership team at 360 Concussion Care. She has received personal fees for the provision of medicolegal opinions. M.C.L. has received personal fees from Abbvie, Lundbeck, and Pfizer, and for the provision of medicolegal opinions. R.J.W. reports no disclosures relevant to the manuscript. K.C. reports no disclosures relevant to the manuscript. H.W.S. reports receiving personal fees from AbbVie, Lundbeck, Pfizer and Teva, and non-restricted research grants from NovoNordisk Foundation. K.J. reports no disclosures relevant to the manuscript. A.B.D. reports no disclosures relevant to the manuscript. I.T. reports no disclosures relevant to the manuscript. F.D. reports no disclosures relevant to the manuscript. R.Z.’s program of research has received financial support through competitively funded research grants from Canadian Institutes of Health Research (CIHR), Ontario Neurotrauma Foundation (ONF), Physician Services Incorporated (PSI) Foundation, CHEO Foundation, uOBMRI, OBI, National Football League (NFL), Ontario Ministry of Health (MOH), Public Health Agency of Canada (PHAC), Health Canada, Parachute Canada and Ontario SPOR Support Unit (OSSU). RZ is supported by a Tier 1 Clinical Research Chair in Pediatric Concussion from University of Ottawa. All grant funding goes directly to the institution. R.Z. sits on the board of directors for North American Brain Injury Society (NABIS), which is a volunteer (unpaid) role. Finally, R.Z. is Scientific Director and a minority shareholder of 360 Concussion Care (a learning health system and network of interdisciplinary concussion clinics in Ontario); no proceeds have been transferred to R.Z.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
